Please Wait
Applying Filters...
menu
    • menu
    Excipient Market Overview: Evonik launches high-purity excipients; India mandates disclosures from March 2026

    Data Compilation
    #PharmaFlow

    Pipeline Prospector October 2025: Novartis to buy Avidity for US$ 12 bn; FDA approves Bayer’s med to treat hot flashes

    Stock Recap
    #PipelineProspector

    Menu

    Nilvadipine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to download the data

    Last Updated on PharmaCompass Virtual Booth Country Holder DMF No. Subject Submission Date Status Type GDUFA DMF Review GDUFA Review Date GDUFA Payment Date
    31/10/2025 Astellas Pharma
    Japan
    		 FUJISAWA PHARMACEUTICAL CO LTD 6052 NILVADIPINE (FK 235,FR 34235) 1985-10-07 Inactive II N/A
    31/10/2025 Astellas Pharma
    Japan
    		 FUJISAWA PHARMACEUTICAL CO LTD 14287 NILVADIPINE 1999-07-12 Inactive II N/A